On June 9, 2025, Keros Therapeutics, Inc. announced that it had held its annual meeting of shareholders on June 4, 2025, and declared the voting results. Accordingly, the nominees, Mary Ann Gray and Alpna Seth, were elected and appointed as directors. The Company also stated that it has concluded its previously announced review process to evaluate strategic alternatives to maximize stockholder value for the Company.
As a result of this process, the Company?s Board of Directors unanimously determined to initiate a process to return $375 million of excess capital to stockholders. The terms and structure of this capital return remain under consideration and are expected to be announced at a future date.
